US 11,786,609 B2
Lipid compound as well as lipid vector, nucleic acid lipid nanoparticle composition, and pharmaceutical preparation comprising the same
Ke Huang, Suzhou (CN); Chaoxuan Jing, Suzhou (CN); Yingwen Li, Suzhou (CN); Yinjia Gao, Suzhou (CN); Yuping Liu, Suzhou (CN); and Zhenhua Sun, Suzhou (CN)
Assigned to PURECODON (HONG KONG) BIOPHARMA LIMITED, Hong Kong (CN)
Filed by PURECODON (HONG KONG) BIOPHARMA LIMITED, Hong Kong (CN)
Filed on Jul. 26, 2022, as Appl. No. 17/873,404.
Application 17/873,404 is a continuation of application No. PCT/CN2022/080352, filed on Mar. 11, 2022.
Claims priority of application No. 202110483495.8 (CN), filed on Apr. 30, 2021; and application No. 202110662426.3 (CN), filed on Jun. 15, 2021.
Prior Publication US 2022/0378938 A1, Dec. 1, 2022
Int. Cl. A61K 9/127 (2006.01); A61K 9/51 (2006.01); C07C 219/06 (2006.01); C07C 291/00 (2006.01); C07C 323/52 (2006.01); C07C 327/06 (2006.01); C12N 15/88 (2006.01); A61K 48/00 (2006.01)
CPC A61K 48/005 (2013.01) [A61K 9/127 (2013.01); A61K 9/5123 (2013.01); A61K 48/0033 (2013.01); C07C 219/06 (2013.01); C07C 291/00 (2013.01); C07C 323/52 (2013.01); C07C 327/06 (2013.01); C12N 15/88 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A compound of formula (I-1-1), or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a solvate, a chelate, a non-covalent complex or a prodrug thereof,

OG Complex Work Unit Chemistry
wherein
each of A is independently one or more substituents selected from the group consisting of —O(C═O)—, —(C═O)O—, —C(═O)S—, —SC(═O)—, —NHC(═O)—, and —C(═O)NH—;
each of R1, R2, R3 and R4 is independently an alkyl group containing 1 to 16 carbon atoms;
R5 is a C1-12 alkyl group; and
each of a, b, d and e is independently any integer ranging from 0 to 14.